Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by Aug 2025. Click for my MDGL update.

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

THE price of Mounjaro is set to soar, The Sun revealed yesterday – leaving slimmers desperate and worried at how they will afford the ‘life-changing’ drug. With the price hike ...

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...